Sentence examples for increasing psa values from inspiring English sources

At our centres, the indications for bone scan examinations in prostate cancer patients are mainly PSA in blood >20 and/or high GS (>8), increasing PSA values (biochemical progression) and bone pain (symptomatic progression).

At 10 years of follow-up, approximately 35% of men treated with RP and 50% of men treated with EBRT will develop biochemical recurrence [6], defined as two consecutive increasing PSA values >0.2 ng/mL after RP and >2 ng/mL above the nadir after EBRT [7].

This method allows more accurate and complete prostate sampling at subsequent re-biopsy when the first biopsy is negative but the patient continues to have increasing PSA values.

However, no significant changes in PSA kinetics were observed in any patients and increased PSA-specific T cell reactivity was only observed in patients in the highest dose cohorts (4 of 15) [47].

Interestingly, we show for the first time that fluoxetine tended to increase PSA-NCAM immunoreactivity in adolescent rats.

Using only evaluable PSA values, PSA-DT was calculated using an algorithm calculator (http://mskcc.org/applications/nomograms/prostate/PsaDoublingTime.aspx).aspx

Sensitivity for detection of recurrence was 95.7 % for PSA-values ≥ 2ng/ml, 81.4 % for PSA-values of 1-2 ng/ml, 76% for PSA-values 0.5-1 ng/ml, and 51% for PSA values ≤ 0.5 ng/ml.

PSA values used to calculate the PSA-DT were evaluated by a study-independent, blinded reviewer.

Thus, PET/CT should not, theoretically, primarily benefit patients with high PSA values, but rather those with low PSAs [21].

Even though the literature sets the positivity of 68Ga-PSMA PET/CT dependent on the PSA-value (PSA < 0.5), in this study only 6 patients have PSA-values < 0.5 ng/mL, and 27 patients have PSA > 1 ng/mL (Table 1).

The plot of Area vs. Concentration in Figure 3 for the light peptide group of one typical peptide bi0161 (PSA-IVG) shows that for Area the variance increases with increasing mean value.